Humana Inc. $HUM Shares Sold by Atlas Brown Inc.

Atlas Brown Inc. lowered its position in shares of Humana Inc. (NYSE:HUM) by 62.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,436 shares of the insurance provider’s stock after selling 4,049 shares during the quarter. Atlas Brown Inc.’s holdings in Humana were worth $624,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Rosenberg Matthew Hamilton lifted its position in Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after purchasing an additional 68 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in Humana during the 2nd quarter worth approximately $32,000. Mather Group LLC. purchased a new position in shares of Humana during the 3rd quarter worth approximately $34,000. AlphaCore Capital LLC purchased a new position in shares of Humana during the 2nd quarter worth approximately $39,000. Finally, Private Wealth Management Group LLC lifted its holdings in shares of Humana by 47.5% in the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after buying an additional 48 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on HUM shares. Sanford C. Bernstein restated an “outperform” rating and issued a $344.00 price target on shares of Humana in a research note on Tuesday, January 6th. Cantor Fitzgerald cut their price objective on Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a research report on Thursday, February 12th. Leerink Partners reduced their target price on Humana from $267.00 to $185.00 and set a “market perform” rating for the company in a report on Thursday, February 12th. Guggenheim decreased their target price on shares of Humana from $312.00 to $252.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Humana in a research note on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $225.48.

Insiders Place Their Bets

In other Humana news, insider Sanjay K. Shetty bought 810 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was purchased at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the acquisition, the insider owned 11,657 shares of the company’s stock, valued at $2,158,992.97. The trade was a 7.47% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

Humana Stock Performance

NYSE HUM opened at $170.12 on Tuesday. The business has a 50 day moving average price of $200.03 and a 200 day moving average price of $241.73. The company has a market capitalization of $20.42 billion, a P/E ratio of 17.32, a PEG ratio of 1.82 and a beta of 0.44. Humana Inc. has a 1-year low of $163.11 and a 1-year high of $315.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. During the same period in the previous year, the business earned ($2.16) earnings per share. Humana’s quarterly revenue was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Friday, March 27th. Humana’s dividend payout ratio is presently 36.05%.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.